In 1988, when Chen Xueli, 37 years old, was the director of Tiancun Welfare Center in Huanjui District, Weihai, he found that disposable infusion devices have a lot of business opportunities, so he borrowed 25,000 yuan from the tax office to create a small medical equipment factory - Shandong Province, Weihai, General Factory of Medical Polymer Products. At the beginning of the business, this small factory only produces disposable infusion sets, and later gradually produces syringes, blood transfusion sets, infusion needles and other products. Relying on these low-value medical consumables, Chen Xueli is at the helm of this small factory to develop and grow rapidly.
Talent, which became the top priority of Weigao's development at that time. In the early 1990s, there was no national standard for disposable medical devices. In Chen Xueli three times "softly", Weigao "knocked open" the Shandong Institute of Medical Devices, Qingdao Ocean University and other units of the "door of cooperation", built the country's first standardized production workshop for disposable infusion devices. The first standardized production workshop for disposable infusion set. Immediately after, Chen Xueli and drummed up the courage, head into the Changchun Institute of Applied Chemistry of the Chinese Academy of Sciences door.
In 1999, Weigao Medical Polymer Research Center was established in Changchun. The following year, Yin Jinghua, then director of the Institute's Polymer Application Research Laboratory, came to Weigao to serve as chief engineer, creating a precedent in the country for researchers to serve in enterprises. Yin Jinghua's arrival also directly gave birth to the localization of intravenous indwelling needles. Today, one out of every five intravenous needles in China comes from Weigao.
In Chen Xueli's view, the innovation of Weigao's development today is ultimately reflected in its products, but actually in its ideology. With a high-quality R&D team and large investment in R&D, Weigao not only upgrades its traditional infusion series products, but also establishes flexible and diversified cooperation methods and introduces experts and talents in the fields of cardiac intervention, orthopaedics and blood purification, so as to ask for productivity and added-value to the products with high-tech content.
From aiming at "China's first-class" to "world-class". Driven by technological innovation, Weigao has established a wide range of technological alliances over the years, cooperated with the Chinese Academy of Sciences, the Chinese Academy of Engineering and other domestic first-class scientific research institutions to set up more than 30 R & D centers and joint laboratories, and has more than 100 academicians serving as technical advisers to the enterprise. In addition, Weigao has also introduced a number of industry leaders through equity cooperation to jointly develop high-end products.
Once upon a time, even a needle in China's medical device industry had to be imported from Japan, but now, adhering to the core values of "conscience, sincerity and loyalty", Weigao has developed from a township enterprise into China's largest medical device manufacturer. At present, Weigao owns more than 1,000 varieties of medical devices and medicines, more than 200,000 specifications, more than 1,500 patents, including more than 400 invention patents, more than 30 listed in the national project, won 4 National Science and Technology Progress Award, National Technology Invention Award, more than 100 kinds of products to break the monopoly of foreign countries, and save more than 300 billion yuan for the country. 2021, Weigao's sales revenue is more than 50 billion yuan. exceeded 50 billion yuan. Such results, in the eyes of Chen Xueli, is the enterprise innovation content "solid" embodiment.
"Together with the white messenger, create a healthy future" has always been Weigao Group adhering to the corporate mission and social responsibility, as a national brand in the medical device manufacturing industry, Weigao has taken practical action to carry out the important task of actively practicing the strategy of healthy China. In the future, Weigao will continue to strengthen the digital transformation, enhance the innovation drive, and help Shandong's high-quality development.